Mariana Avalos

Mariana Avalos

Auto-generated profile, based on publicly available information

Mariana Avalos

Department of Molecular Biotechnology, Institute of Biology, Leiden University, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2024 in Nature Chemistry
Verified
Journal Article
Open access
PDF file
ABAlexander T. Bakker
Alexander T. Bakker
IKIoli Kotsogianni
Ioli Kotsogianni
MAMariana Avalos
Mariana Avalos
JPJeroen M. Punt
Jeroen M. Punt
BLBing Liu
Bing Liu
MSMario van der Stelt
Mario van der Stelt
Bacteria have evolved resistance to nearly all known antibacterials, emphasizing the need to identify antibiotics that operate via novel mechanisms. Here we report a class of allosteric inhibitors of DNA gyrase with antibacterial activity against fluoroquinolone-resistant clinical isolates of Escherichia coli. Screening of a small-molecule library revealed an initial isoquinoline sulfonamide hit, which was optimized via medicinal chemistry efforts to afford the more potent antibacterial LEI-800. Target identification studies, including whole-genome sequencing of in vitro selected mutants with resistance to isoquinoline sulfonamides, unanimously pointed to the DNA gyrase complex, an essential bacterial topoisomerase and an established antibacterial target. Using single-particle cryogenic electron microscopy, we determined the structure of the gyrase–LEI-800–DNA complex. The compound occupies an allosteric, hydrophobic pocket in the GyrA subunit and has a mode of action that is distinct from the clinically used fluoroquinolones or any other gyrase inhibitor reported to date. LEI-800 provides a chemotype suitable for development to counter the increasingly widespread bacterial resistance to fluoroquinolones.